Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06204159 · ClinicalTrials.gov registry record · NA
Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
A NA study of Hepatocellular Carcinoma and Neuroendocrine Tumors, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT06204159 is a NA study of Hepatocellular Carcinoma and Neuroendocrine Tumors that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 12 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06204159, a NA study of Hepatocellular Carcinoma and Neuroendocrine Tumors, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to compare CT scan of the coverage of tumors treated with TACE using End Hole catheters to those treated with the TriNav catheter that alters tissue pressure. Both catheters are FDA approved for delivery of TACE. • Is there a difference in CT appearance with delivery in the type of catheter used during the TACE procedure? Participants will be asked to undergo a TACE procedure, a CT scan and review of their medical record to compare End Hole and TriNav catheters during TACE procedures.
Conditions Studied
Interventions
- DEVICE TACE Catheters
Study Locations (2)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
- University of Pennsylvania, Department of Radiology, Interventional Radiology Division - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06204159
The ClinicalTrials.gov registry entry for NCT06204159 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (95% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which TACE Catheters is the first listed.
NCT06204159 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06204159 about?
NCT06204159 is a clinical study titled "Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery". The goal of this clinical trial is to compare CT scan of the coverage of tumors treated with TACE using End Hole catheters to those treated with the TriNav catheter that alters tissue pressure. Both catheters are FDA approved for delivery of TACE. • Is there a difference in CT appearance with deliv...
What is the current status of trial NCT06204159?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2024-02-01. Estimated completion is 2026-06-30.
What conditions does trial NCT06204159 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Neuroendocrine Tumors.
What interventions are being tested in trial NCT06204159?
The interventions under investigation include: TACE Catheters (DEVICE).
Who is sponsoring clinical trial NCT06204159?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06204159 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
-
Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
RECRUITING · NA
-
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.